Therapeutic effect of teprenone combined with famotidine on gastrointestinal injury caused by antiplatelet drugs
Received:April 04, 2019  
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2019.08.122
Key words:gastrointestinal tract; antiplatelet drug; teprenone
Author NameAffiliationE-mail
CHEN Zhen-Dao Department of Gastroenterology, Huazhou People′s Hospital of Guangdong Province, Huazhou 525100, China czd2043@sina.com 
SU Yi Department of Gastroenterology, Huazhou People′s Hospital of Guangdong Province, Huazhou 525100, China  
CHEN Hao Department of Gastroenterology, People′s Hospital of Guangdong Province, Guangzhou 510000, China  
ZHU Bin Department of Gastroenterology, Huazhou People′s Hospital of Guangdong Province, Huazhou 525100, China  
WANG Ya-Rui Department of Gastroenterology, Huazhou People′s Hospital of Guangdong Province, Huazhou 525100, China  
Hits: 71
Download times: 96
Abstract:
      Objective To observe the efficacy of teprenone combined with famotidine in the prevention and treatment of gastro-intestinal injury caused by antiplatelet drugs. Methods A total of 84 patients with gastrointestinal injuries caused by antiplatelet drugs admitted in Huazhou People′s Hospital from August 2016 to November 2018 were enrolled in this study. They were divided into 3 groups (n=28), that is, proton pump inhibitor group (PPI, pantoprazole), H2 receptor antagonist group (H2RA, famotidine), and combined treatment group (teprenone and famotidine). All patients continued to receive antiplatelet therapy. The related indicators were observed before and in 6 months after treatment, and the results were compared among the 3 groups. SPSS statistics 24.0 was used to perform the statistical analysis. Results After treatment, the combined treatment group had significantly higher prostaglandin E2 level [PGE2, (83.46±16.83) vs (46.61±14.53) vs (55.67±18.49)ng/L], but obviously lower thromboxane B2 [TXB2,(139.96±48.69) vs (297.38±44.09) vs (173.82±51.25)pg/L] when compared with the PPI group and the H2RA group. But the gastric acid secretion in the combined treatment group was higher than the PPI group and lower than the H2RA group [(3.86±0.67) vs(2.29±0.56) vs(4.97±0.89)mmol/h, P<0.05]. What′s more, the modified Lanza scale scores of the gastric and duodenal mucosa in the combined treatment group were significantly lower than those in the PPI group and the H2RA group [(0.76±0.37) vs (3.38±2.11) vs (3.04±1.93), (0.81±0.32) vs (3.19±1.52) vs (2.91±1.49), P<0.05]. The incidences of adverse reactions were also significantly lower in the combined treatment group than the other 2 groups (17.9% vs 53.6% vs 28.6%, P<0.05). Conclusion The combination of teprenone and famotidine exerts significant efficacy and has few adverse reactions in the prevention and treatment of gastrointestinal injuries caused by antiplatelet drugs, which is worthy of clinical application.
Close